INTERIM REPORT

Q2 2026

Neem's Hill AB (publ)

Neem’s Hill AB (publ)

January - June 2026

- Net sales amounted to 6,090 KSEK (6,313)
- Profit/loss after financial items amounted to -4,195 KSEK (-4,265)
- Earnings per share amounted to -0,16 SEK (-0,18)
- Cash flow from operating activities amounted to -2,923 KSEK (-1,743)
- All orders were delivered by the end of the period

April – June 2026

- Net sales amounted to 3,292 KSEK (3,841)
- Profit/loss after financial items amounted to -2,622 KSEK (-943)
- Earnings per share amounted to -0,10 SEK (-0,04)
- Cash flow from operating activities amounted to -1,780 KSEK (-504)

Events during the reporting period

- ChemoTech announces outcome of the directed share issue
- Scandinavian ChemoTech secures SEK 6 million growth loan from a large Swedish financial institution

Events after the reporting period

- ChemoTech’s TSE Reports 97% complete remission and stronger than expected clinical results in Equine
- Scandinavian ChemoTech AB changes name to Neem’s Hill AB

Word from the CEO

The second quarter of 2026 was another strong quarter for Neem's Hill, with sales ending just shy of the record-breaking second quarter last year.

The composition of our revenue continued to develop positively. Treatment kit sales increased by 52% in the first half of 2026. This reflects increasing clinical activity among our customers and strengthens the recurring revenue base created by our growing installed base, which reached almost 60 vetIQure systems at the end of the quarter.

Growing clinical evidence and academic recognition

One of the most important developments during the period was the publication of the abstract from the retrospective equine study conducted at the Norwegian University of Life Sciences.

The study included 26 horses with 66 equine sarcoid lesions treated with vetIQure TSE and reported a 97% complete remission rate at the eight-month follow-up. Of clinical and practical importance, 23 of the 26 horses were treated under standing sedation rather than general anesthesia. This may reduce treatment complexity and risk while making the procedure more accessible to veterinary clinics and horse owners.

The abstract was presented at the European College of Veterinary Surgeons' scientific meeting in Liverpool. Scientific publications and presentations are important for building confidence among clinicians, universities and larger veterinary organizations and for supporting broader adoption of vetIQure.

During the quarter, we also received an order from the University of Copenhagen, making it the third veterinary university in Scandinavia to acquire a vetIQure system.

The University of Copenhagen has extensive experience with first-generation static electroporation technologies and is a recognized center in the field, including within Human Care. We therefore view the university's decision to adopt vetIQure as an important reference for the market, and as a recognition of the next generation of electroporation technology that we call Tumor Specific Electroporation, or TSE.

With academic users and clinical collaborations now established across Sweden, Norway, Denmark, the United Kingdom and Turkey, vetIQure is supported by a growing international network of veterinary academic- and clinical institutions. Feedback received at recent scientific conferences also indicates increasing interest among clinics and specialists in potentially upgrading from traditional static electroporation systems to TSE.

Continued commercial development

Animal Care remains the Group's principal commercial growth driver. Our strategy continues to focus on two priorities: increasing the number of active vetIQure users and increasing treatment activity within the existing customer base. In the USA, significant progress was made in raising product awareness, generating interest, and encouraging product trials among key accounts.

The strong development in treatment kit sales during the first half of the year demonstrates the value of this strategy. As more clinics gain experience with TSE and integrate the technology into their oncology offering, treatment kits are becoming an increasingly important source of recurring revenue.

During the quarter, we strengthened our commercial and application support organization by adding the equivalent of two and a half full-time resources within sales, marketing, clinical applications and customer support.

Among these additions is a dedicated application specialist with hands-on experience from over hundred TSE treatments and previous experience with the older first-generation static electroporation systems. This combination of practical treatment experience and technology knowledge strengthens our ability to support clinics, accelerate adoption, increase utilization and help customers achieve consistent clinical outcomes.

These additional resources also increase our capacity to develop new opportunities, support customers during implementation and training, and help existing clinics expand their use of vetIQure. Their contribution is expected to become increasingly visible as they build market knowledge and customer relationships.

Progress within Human Care

Human Care remains an important part of the Group's long-term value potential, with India serving as our principal market for continued clinical development.

After the end of the quarter, the nineteenth patient was treated in our ongoing clinical study in India. Each treated patient contributes additional clinical experience and knowledge regarding the use of TSE in advanced and difficult-to-treat tumors.

We continue to evaluate additional clinical collaborations in India that may broaden the clinical application of the technology and support the development of a scalable pathway for TSE within human oncology.

Continued platform development

Our R&D activities continue to advance across software solutions, new electrode designs including work to extend the validated shelf life of our treatment kits, giving clinics greater flexibility in inventory planning and reducing the risk of kits reaching their expiration date before use. We believe these improvements will be highly valued by our customers and support more efficient purchasing and clinical operations.

A new chapter as Neem's Hill

During the quarter, the Annual General Meeting approved the change of name from Scandinavian ChemoTech AB to Neem's Hill AB. This marks the beginning of a new chapter for the Group and more clearly reflects the structure and direction of our operations.

Neem's Hill is the listed parent and holding company for two distinct business areas: Animal Care and Human Care. Both are based on our patented TSE technology, while each follows its own clinical and commercial pathway.

The new structure provides greater strategic and financial flexibility. It enables the different business areas to be developed and funded independently as opportunities arise, while allowing the Group to add complementary technologies or operations through partnerships or acquisitions. Individual business areas may also be financed, partnered, expanded or, when appropriate, divested independently. This gives Neem's Hill a broader range of options for creating and realizing shareholder value over time.

The Annual General Meeting also approved a directed share issue to a limited number of existing lenders. By converting part of the Group's outstanding loan obligations into equity, the transaction strengthened the capital structure and reduced financial indebtedness.

Looking ahead

The first half of 2026 combined continued sales in vetIQure systems, with a significant increase in recurring treatment kit revenue, which more importantly means that the average treatment activity across the installed base continues to increase month by month.

This means that more patients are being treated, more successful clinical outcomes are being achieved, and more veterinarians are gaining first-hand experience of the clinical value of TSE. Each successful treatment strengthens confidence in the technology and demonstrates both its clinical benefit for patients and its commercial value for veterinary clinics.

As awareness of TSE continues to grow, we believe this expanding body of practical experience can support broader adoption, with more clinics recognizing the value of moving from traditional static electroporation systems to the next generation of electroporation technology.

Our focus for the remainder of the year is to expand the number of active vetIQure users, increase utilization within the installed base and support broader adoption through clinical evidence, academic partnerships and high-quality customer support.

With a clearer Group structure, growing recurring revenue and increasing recognition of TSE, we continue to strengthen the foundation for sustainable growth and long-term shareholder value.

I would like to thank our employees, consultants, clinical partners, customers and shareholders for their continued commitment and support.

Mohan Frick – CEO Neem's Hill AB (publ)

About the Company

Neem's Hill AB (publ), corporate registration number 556937-9547, formerly Scandinavian ChemoTech AB (publ), is a listed holding, investment, and development company operating within veterinary medicine, human medicine, and related technologies.

The Company's activities include business development and organizational consulting for operations within these fields. Neem's Hill also owns and manages shares, ownership interests, securities, intellectual property, and other real and personal property, and conducts activities compatible with these purposes.

Neem's Hill was founded in Lund, Sweden, in 2015 by Mohan Frick, Dr. Göran Hellers, and Professor Emeritus Bertil Persson, who is widely recognized for his pioneering work within electroporation.

The Group combines experience in medical technology, radiation physics, surgical oncology, clinical development, product development, regulatory affairs, business development, and international commercialization.

Neem's Hill's role is to establish, develop, own and manage investments, innovations, and businesses that address important clinical and commercial needs through medical technology, strong intellectual property, clinical development, and scalable business models.

Today, the Group is built around two distinct business areas and investments:

- Human Care
- Animal Care

Each business area has its own company structure, product platform, customer groups, clinical strategy, geographic market focus, and commercial organization.

Human Care is represented by Scandinavian ChemoTech and its IQwave™ product platform. The business area is primarily focused on establishing Tumor Specific Electroporation™ as a treatment option for head and neck cancer and other solid, tissue-based tumors, with a current clinical and commercial focus on India, Asia, and Southeast Asia.

Animal Care is represented by VQ Animal Care Inc., headquartered in the United States, and its vetIQure™ product platform. The business area focuses primarily on the North American and European veterinary markets and provides veterinary oncologists, surgeons, and other clinicians with a portable platform for treating tumors in companion animals and horses.

Both business areas currently use the Group's patented Tumor Specific Electroporation™ technology. TSE therefore represents an important shared technological and intellectual-property asset within Neem's Hill's current portfolio.

Neem's Hill's broader purpose is, however, to act as a holding-, investment-, and development company capable of establishing, acquiring, developing, and managing additional businesses, technologies, assets, and investments over time. Future investments do not necessarily need to be based on TSE, provided they are compatible with the Company's purpose and strategic focus within veterinary medicine, human medicine, and related technologies.

Tumor Specific Electroporation™

Tumor Specific Electroporation™ is a patented technology platform developed to enable more tumor-specific and tissue-preserving cancer treatment.

TSE is designed to increase the uptake of therapeutic molecules in cancerous tissue, allowing low doses of anticancer drugs to be concentrated more effectively within the treated tumor. This may enable treatment with substantially lower doses of chemotherapy than conventional systemic cancer treatment while reducing exposure to surrounding healthy tissue.

The technology is designed to promote apoptosis, or programmed cell death, while minimizing uncontrolled cell death, tissue destruction, and necrosis. Depending on the indication, tumor location, and individual patient requirements, TSE treatment can often be performed without general anaesthesia in both human and animal patients.

Conventional electroporation systems typically deliver a fixed and predetermined voltage. However, the electrical resistance of tissue may vary significantly between tumors, tissue types, patients, and different stages of treatment.

When the voltage remains static while tissue resistance changes, the resulting current may vary in an uncontrolled and unpredictable manner. Consequently, the total energy delivered to the tissue may also vary, increasing the risk of excessive energy delivery, tissue heating, coagulation, necrosis, and damage to surrounding healthy tissue.

TSE uses advanced hardware and software to monitor the electrical response of the tissue and dynamically adjust the voltage throughout the pulse sequence. The system provides real-time feedback, treatment warnings, and integrated safety functions intended to keep the treating physician or veterinarian in control throughout the procedure.

By adapting the voltage to the response of the tissue, TSE is designed to provide more controlled electrical stimulation, promote effective and reversible electroporation, and reduce the risk of excessive current and uncontrolled energy delivery.

Technology and Patent portfolio

The TSE technology platform is protected through three principal patented product areas:

- The TSE pulse-generation system
- The handheld treatment probe
- The sterile treatment electrodes

The Group's granted patents protect essential elements of the technology, including:

- The characteristics and functions of the pulse generator responsible for generating the TSE pulse
- The handheld probe, which allows the treatment electrodes to be positioned and moved in different directions
- The ability to treat both large and small tumors, including tumors located in anatomically restricted areas
- Specially designed electrodes intended for treating deeper-seated tumors

Commercial Products and Business Model

Neem's Hill has developed two commercially viable product platforms within its current business areas:

- IQwave™ for human medicine within Human Care
- vetIQure™ for veterinary medicine within Animal Care

Both systems are portable and can be transported between hospitals, clinics, and treatment locations.

The business model is based primarily on revenues from the sale, leasing, or placement of the treatment systems, together with recurring sales of sterile single-use treatment kits and electrodes.

Commercialization is conducted through a combination of direct sales, distributors, clinical partnerships, reference centers, and Centers of Excellence.

Within Human Care, the Group has established distributor and commercial relationships in selected markets in Asia, Africa, and Europe.

Within Animal Care, commercial activities are primarily conducted directly in the United States and Western Europe. The Group also collaborates with leading veterinary institutions and specialist clinics, including Equitom in Belgium and the Royal Veterinary College in London.

Regulatory and Quality Management

In 2021, the Group obtained CE certification for the IQwave™ 3.0 electroporation system.

The system holds an EC certificate issued by ECM, Ente Certificazione Macchine, Italy, under the applicable European medical device regulatory framework.

The Group's quality management system is certified in accordance with ISO 13485:2016, Medical devices — Quality management systems — Requirements for regulatory purposes.

Human Care and Animal Care products are commercialized in accordance with the regulatory requirements applicable in each respective market.

Listing

Neem's Hill AB's Class B shares are listed on Nasdaq First North Growth Market in Stockholm under the ticker NEEMS.

Redeye Nordic Growth AB is the Company's Certified Adviser.

Financial Information

Scope of the Report

This interim report covers the period 1 January – 30 June 2026. Figures in brackets indicate the outcome for the corresponding period last year. Amounts are stated in KSEK.

Sales & Results

Net sales amounted to 3,292 KSEK (3,841) in the second quarter. Total sales for the first six months amounted to 6,090 KSEK (6,313). All sales originated from Animal Care. All sales in the Parent Company were sales to Group Companies.

Animal Care has short lead time from order to delivery, and most orders are delivered almost immediately. All orders were delivered by the end of the quarter.

Operating loss amounted to -1,984 KSEK (-690) for the second quarter and -3,363 KSEK (-3,257) for the first six months. Other external costs are higher than in the previous quarter due to higher other management costs.

Net loss amounted to -2,622 KSEK (-943) for the second quarter. Accumulated net loss amounted to -4,195 KSEK (-4,265).

EBITDA amounted to -1,755 KSEK (-1,139) for the parent company, including Human Care and 270 KSEK (939) for Animal Care for the second quarter.

Other external costs were higher compared to last year, and Personnel costs were lower due to the Company presently having fewer employees and more consultants.

Currency Risk

The Company is exposed to fluctuations in a few currencies. There is therefore a risk that exchange rate changes may affect the Company's results and financial position. The Group generates most of its revenue in USD but also incurs a significant portion of its cost base in USD.

The exchange rate for 1 EUR is 11,09 SEK (11,15) and 1 USD is 9,74 (9,51) as of June 30 according to the Swedish central bank.

Customs duties and tariffs

The Group is exposed to tariffs and customs duties in several markets including USA. The Group complies with the applicable regulations and laws in the respective countries and tries to streamline deliveries to keep the associated costs down.

Investments

Investments in intangible non-current assets amounted to 2,979 KSEK (4,460) and mainly related to the activation of patents and costs associated with the CE marking. Investments made during the first six months amounted to 165 KSEK.

The company reports internally accumulated intangible fixed assets. This means that all expenses related to production of an internally accrued intangible fixed asset, are capitalized and amortized during the asset's estimated lifespan, provided that certain criteria are met.

Accumulated tangible assets amounted to 162 KSEK (3).

Financial Position & Financing

Cash flow from operating activities amounted to -1,780 KSEK (-504) for the second quarter and for the first six months it was -2,923 KSEK (1,743).

Cash and cash equivalents amounted to 1,456 KSEK (517) as of June 30.

The company had loans of a total of 5,030 KSEK (6,067) from external lenders and board members as of June 30.
During the quarter the Company was granted an overdraft facility of 2,500 KSEK, of which 2,000 KSESK had been used and 500 KSEK remained as an overdraft by June 30.
During the quarter a loan of 6,000 KSEK was granted by a large financial institution.

During the quarter, a directed issue was carried out, which raised 2,550 KSEK to the company. The proceeds were offset against existing loans.

Efforts to identify and secure optimal financing solutions for the Company are continuously ongoing.

Equity for the Group amounted to 1,520 KSEK (2,193) and the equity/assets ratio amounted to 14% (18) as of June 30.

Accounts Receivable

Accounts receivable amounted to 1,716 KSEK (946) at the end of the quarter.

Organization

The Group had 1 (2) employees and 8 dedicated consultants, of which 4 work full-time. 2,5 are new within sales and marketing for Animal Care.
In addition to employees, Neem's Hill hires consultants with cutting-edge expertise when needed.

Research & Development

Development is run in-house in collaboration with external clinics and consultants. The development work is focused on new development and further refinement of the current product portfolio.

Insurance

Neem's Hill has corporate insurance. The insurance cover is subject to continuing evaluation, and the Board of Directors assesses that the corporate insurance is adapted to the current scope of the business.

Disputes

Neem's Hill is not a party to any legal dispute or arbitration. Nor is the Board aware of any circumstances that could lead to any such legal proceedings or arbitration being initiated.

Significant Risks & Uncertainties

The company's significant estimates and assessments are described in the Annual Report for 2025 in the Directors Report. No significant changes have occurred since then.

Conditions for Continued Operations

The financial information in this report has been prepared based on the assumption of going concern. The company has historically reported losses. In preparing the interim report, management and the Board of Directors have based their assumptions on existing cash and cash equivalents and expected financing through loans and new share issues as well as increased sales. When estimating future expenses, management has considered that certain expenses are under management's control and can thus be eliminated or postponed to the future. However, additional funding will be required to maintain operations for the next twelve months. Management is aware of uncertainties in the estimation of future cash flows as well as uncertainty in the financing of operations and is actively working on these issues. If the Group is unable to continue to operate for any reason, it may affect the Group's ability to realize the carrying amount of its assets, particularly related to capitalized expenditure for research and development, as well as to pay debts on a timely manner and to the amounts recorded in the Group's interim report.

Valuation of Intangible Assets

The reported capitalized expenditure for research and development is subject to management's impairment testing. The most critical assumption, evaluated by management, relates to whether the intangible asset is expected to generate future economic benefits, at least equivalent to the carrying amount of the intangible asset. Management's assessment is that the expected future cash flows are sufficient to justify the carrying amount of the intangible assets, which is why no write-down has been made. However, the valuation is based on and dependent on the conditions for continued operations.

Company information & Group structure

Neem's Hill AB (publ), 556937–9547 is the parent company of three wholly owned subsidiaries, Vetiqure AB (SE), VQ Animal Care (US) and Chemotech International (SG).

Group structure:



Disclaimer

This financial report contains statements that may be future-oriented estimates.

Predictions are valid only on the date they are made. All predictions are subject to uncertainty. In view of this, actual results may differ from those stated in this report.

Accounting Principles

The Company applies the Annual Accounts Act and the Swedish Accounting Standards Board's general guidelines BFNAR 2012:1 (K3) when preparing financial reports.

Audit Review

This interim report has not been reviewed by the Company's auditors.

The share

The number of shares at the end of the year amounted to 26,215,169 of which 2,412,857 were Class A shares (voting rights 3) and 23,802,312 Class B shares (voting rights 1).

The Company has two ongoing subscription warrant programs: Series TO4 and TO5. Full exercise of all subscription warrants would result in 1,160,000 shares in the Company, corresponding to a dilution effect of approximately 4,8%

Shareholders

The four largest shareholders were CEO Mohan Frick, Avanza Pension, Anders and Britt-Marie Frick and BEngström Förvaltning AB, who together held a total of 34,21% of capital and 43,96% of votes as of June 30, 2026.

Largest owners June 30, 2026	No of A-shares	No of B-shares	No of shares Total	No of votes	Percent of capital	Percent of votes
1. Mohan Frick (private or through own company)	1 508 880	1 750 788	3 259 668	6 277 428	12,43%	20,22%
2. Avanza Pension	0	2 866 019	2 866 019	2 866 019	10,93%	9,23%
3. Anders and Britt-Marie Frick	590 546	930 746	1 521 292	2 702 384	5,80%	8,71%
4. B Engström Förvaltning AB	238 805	1 084 955	1 323 760	1 801 370	5,05%	5,80%
5. Tom Asplund	0	1 376 573	1 376 573	1 376 573	5,25%	4,43%
6. Martin Jerndal	0	901 273	901 273	901 273	3,44%	2,90%
7. Amitbir Singh Banga	0	900 000	900 000	900 000	3,43%	2,90%
7. Harbir Singh Banga	0	900 000	900 000	900 000	3,43%	2,90%
9. Nordnet Pensionsförsäkring	0	796 879	796 879	796 879	3,04%	2,57%
10. Elbema Fastigheter AB	0	554 880	554 880	554 880	2,12%	1,79%
Summa:	2 338 231	12 062 113	14 400 344	19 076 806	54,93%	61,46%
Övriga	74 626	11 740 199	11 814 825	11 964 077	45,07%	38,54%
Totalt	2 412 857	23 802 312	26 215 169	31 040 883	100,00%	100,00%

(Shareholders who are not owner-registered, but whose shares are invested in insurance policies and custody accounts are not included in this list)

Financial information

Unless otherwise stated, amounts are in KSEK (thousands of Swedish kronor)

Group income statement

	2026 Apr-Jun	2025 Apr-Jun	2026 Jan-Jun	2025 Jan-Jun	2025 Jan-Dec
Net sales	3 292	3 841	6 090	6 313	12 285
Work performed by the company for its own use and capitalized	0	0	0	0	0
Other operating income	10	44	181	84	101
Total operating income	3 302	3 885	6 271	6 397	12 386
Goods for resale	-837	-497	-1 206	-1 271	-1 989
Other external costs	-3 616	-2 457	-6 701	-4 854	-11 476
Personnel costs	-329	-986	-632	-2 332	-3 149
Depreciation and write-downs	-499	-490	-1 001	-980	-1 973
Other operating expenses	-5	-145	-94	-217	-262
Total operating expenses	-5 286	-4 575	-9 634	-9 654	-18 849
Operating profit/loss	-1 984	-690	-3 363	-3 257	-6 463
Net financial items	-638	-253	-832	-1 008	-1 593
Profit/loss after financial items	-2 622	-943	-4 195	-4 265	-8 056
Taxes	-	-	-	-	-
Net profit/loss for the year	-2 622	-943	-4 195	-4 265	-8 056

Consolidated balance sheet

ASSETS	2026-06-30	2025-06-30	2025-12-31
Fixed assets			
Intangible assets	2 979	4 460	3 788
Tangible assets	162	3	119
Financial assets	158	157	155
Total fixed assets	3 299	4 620	4 062
Current assets			
Inventories	2 789	3 431	2 794
Current receivables	3 463	3 914	2 676
Cash and cash equivalents	1 456	517	3 668
Total current assets	7 708	7 862	9 138
TOTAL ASSETS	11 007	12 482	13 200
EQUITY AND LIABILITIES			
Equity	1 520	2 193	3 186
Current liabilities	9 487	10 289	10 014
TOTAL EQUITY AND LIABILITIES	11 007	12 482	13 200

Financial Information cont'd

Unless otherwise stated, amounts are in KSEK (thousands of Swedish kronor)

Consolidated cash flow analysis

	2026 Apr-Jun	2025 Apr-Jun	2026 Jan-Jun	2025 Jan-Jun	2025 Jan-Dec
Cash flow from operating activities	-1 780	-504	-2 923	-1 743	-3 744
Cash flow from investing activities	-168	3	-238	9	-426
Cash flow from financing activities	1 949	1	949	1 302	6 889
Total cash flow	1	-500	-2 212	-432	2 719
Cash and cash equivalent at the beginning of the period	1 455	1 017	3 668	949	949
Exchange rate differences in cash and cash equivalents	0	0	0	0	0
Cash and cash equivalent at the end of the period	1 456	517	1 456	517	3 668

Change in group equity

	2026 Apr-Jun	2025 Apr-Jun	2026 Jan-Jun	2025 Jan-Jun	2025 Jan-Dec
Equity at the beginning of the period	1 637	3 697	3 186	5 980	5 980
New share issue, net	2 486	0	2 486	0	5 088
Exchange rate difference	19	-561	43	478	174
Net profit/loss for the year	-2 622	-943	-4 195	-4 265	-8 056
Equity at end of the period	1 520	2 193	1 520	2 193	3 186

Group key figures

	2026 Apr-Jun	2025 Apr-Jun	2026 Jan-Jun	2025 Jan-Jun	2025 Jan-Dec
Earnings per share, SEK	-0,10	-0,04	-0,16	-0,18	-0,34
Equity per share, SEK	0,06	0,09	0,06	0,09	0,12
Average number of shares	25 621 273	23 343 978	25 538 088	23 343 978	24 026 115
Number of shares at end of period	26 215 169	23 343 978	26 215 169	23 343 978	26 215 169
Market price at the end of the period	3,80	1,73	3,80	1,73	5,02

Financial Information cont'd

Unless otherwise stated, amounts are in KSEK (thousands of Swedish kronor)

Parent company income statement

	2026 Apr-Jun	2025 Apr-Jun	2026 Jan-Jun	2025 Jan-Jun	2025 Jan-Dec
Net sales (to group companies)	0	535	505	1 929	5 870
Work performed by the company for its own use and capitalized	0	0	0	0	0
Other operating income	4	26	383	31	1 495
Total operating income	4	561	888	1 960	7 365
Other external costs	-1 147	-1 221	-2 359	-2 679	-11 841
Personnel costs	-91	-212	-174	-740	-1 277
Depreciation and write-downs	-490	-490	-980	-980	-1 959
Other operating expenses	-10	-1	-28	-5	-21
Total operating expenses	-1 738	-1 924	-3 541	-4 404	-15 098
Operating profit/loss	-1 734	-1 363	-2 653	-2 444	-7 733
Net financial items	-259	-360	16	-2 678	-4 265
Profit/loss after financial items	-1 993	-1 723	-2 637	-5 122	-11 998
Taxes	-	-	-	-	-
Net profit/loss for the year	-1 993	-1 723	-2 637	-5 122	-11 998

Parent company balance sheet

ASSETS	2026-06-30	2025-06-30	2025-12-31
Fixed assets			
Intangible assets	2 772	4 460	3 687
Tangible assets	0	0	0
Financial assets	100	100	100
Financial assets, group companies	20 973	24 097	21 398
Total fixed assets	23 845	28 657	25 185
Current assets			
Inventories	3 162	2 402	2 240
Current receivables, group companies	1 405	703	2 190
Current receivables	360	348	290
Cash and cash equivalents	6	32	863
Total current assets	4 933	3 485	5 583
TOTAL ASSETS	28 778	32 142	30 768
EQUITY AND LIABILITIES			
Equity	21 520	23 460	21 671
Current liabilities, group companies	0	38	271
Current liabilities	7 258	8 644	8 826
TOTAL EQUITY AND LIABILITIES	28 778	32 142	30 768

Financial Information cont'd

Unless otherwise stated, amounts are in KSEK (thousands of Swedish kronor)

Group Income statement per business area

	Parent company & Human Care				Animal Care			
	2026 Apr-Jun	2025 Apr-Jun	2026 Jan-Jun	2025 Jan-Jun	2026 Apr-Jun	2025 Apr-Jun	2026 Jan-Jun	2025 Jan-Jun
Net sales	0	0	0	0	3 292	3 841	6 090	6 313
Other operating income	9	26	180	31	1	18	1	53
Total operating income	9	26	180	31	3 293	3 859	6 091	6 366
Goods for resale	0	0	0	0	-837	-497	-1 206	-1 271
Other external costs	-1 414	-1 115	-2 455	-2 501	-2 202	-1 342	-4 246	-2 353
Personnel costs	-329	-36	-632	-790	0	-950	0	-1 542
Other operating expenses	-21	-14	-89	-22	16	-131	-5	-195
Total operating expenses	-1 764	-1 165	-3 176	-3 313	-3 023	-2 920	-5 457	-5 361
EBITDA	-1 755	-1 139	-2 996	-3 282	270	939	634	1 005

Declaration

The Board of Directors and the CEO ensure that the Interim Report Q2 2026 provides a fair overview of the Company's operations, position, and results, and describes significant risks and uncertainties faced by the Company.

The Interim Report Q2 2026 has not been reviewed by the Company's auditor.

Lund 11 August 2026

Robin Sukhia Chairman of the Board	Rolf Ehrnström Board Member	Bengt Engström Board Member
Amitbir Singh Banga Board Member	Mohan Frick Board Member and CEO	

Financial Calendar 2026

• Year-end report 2025	17 February 2026
• Annual report 2025	14 April 2026
• Interim report Q1 2026	28 April 2026
• Annual General Meeting	5 May 2026
• Interim report Q2 2026	11 August 2026
• Interim report Q3 2026	27 October 2026
• Year-end report 2026	23 February 2027

All financial reports are published on www.chemotech.se

For further information, please contact:

Mohan Frick, CEO

E-mail: ir@chemotech.se

Phone: + 46 (0) 10-218 93 00

Neem's Hill AB (publ)

Medicon Village
Scheeletorget 1, 223 63 Lund
010-218 93 00